Zmax is a drug owned by Pf Prism Cv. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 14, 2024. Details of Zmax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6984403 | Azithromycin dosage forms with reduced side effects |
Feb, 2024
(9 months ago) |
Expired
|
| US7887844 | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb, 2024
(9 months ago) |
Expired
|
| US6268489 | Azithromycin dihydrate |
Jul, 2018
(6 years ago) |
Expired
|
| US6068859 | Controlled-release dosage forms of Azithromycin |
May, 2017
(7 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Zmax's patents.
Latest Legal Activities on Zmax's Patents
Given below is the list of recent legal activities going on the following patents of Zmax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jul, 2022 | US7887844 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Jul, 2018 | US7887844 |
| Patent Issue Date Used in PTA Calculation Critical | 15 Feb, 2011 | US7887844 |
| Recordation of Patent Grant Mailed Critical | 15 Feb, 2011 | US7887844 |
| Email Notification Critical | 27 Jan, 2011 | US7887844 |
| Issue Notification Mailed Critical | 26 Jan, 2011 | US7887844 |
| Dispatch to FDC | 10 Jan, 2011 | US7887844 |
| Application Is Considered Ready for Issue Critical | 07 Jan, 2011 | US7887844 |
| Issue Fee Payment Verified Critical | 05 Jan, 2011 | US7887844 |
| Issue Fee Payment Received Critical | 05 Jan, 2011 | US7887844 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Zmax and ongoing litigations to help you estimate the early arrival of Zmax generic.
Zmax's Litigations
Zmax been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 01, 1, against patent number US6268489. The petitioner , challenged the validity of this patent, with ALLEN et al as the respondent. Click below to track the latest information on how companies are challenging Zmax's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6268489 | January, 1 |
Decision
(15 Apr, 1998) | ALLEN et al | |
US patents provide insights into the exclusivity only within the United States, but Zmax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zmax's family patents as well as insights into ongoing legal events on those patents.
Zmax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zmax's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 14, 2024 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zmax Generic API suppliers:
Azithromycin is the generic name for the brand Zmax. 31 different companies have already filed for the generic of Zmax, with Pliva having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zmax's generic
Alternative Brands for Zmax
Zmax which is used for treating bacterial infections., has several other brand drugs in the same treatment category and using the same active ingredient (Azithromycin). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Abbvie |
| |||||
| Baxter Hlthcare Corp |
| |||||
| Cubist Pharms Llc |
| |||||
| Cumberland |
| |||||
| Lg Chem Ltd |
| |||||
| Pfizer |
| |||||
| Pf Prism Cv |
| |||||
| Rempex |
| |||||
| Shionogi Inc |
| |||||
| Wyeth Pharms |
| |||||
| Xellia Pharms Aps |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Azithromycin. Given below is the list of those drugs and companies owning them.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Azithromycin, Zmax's active ingredient. Check the complete list of approved generic manufacturers for Zmax
About Zmax
Zmax is a drug owned by Pf Prism Cv. It is used for treating bacterial infections. Zmax uses Azithromycin as an active ingredient. Zmax was launched by Pf Prism Cv in 2005.
Approval Date:
Zmax was approved by FDA for market use on 10 June, 2005.
Active Ingredient:
Zmax uses Azithromycin as the active ingredient. Check out other Drugs and Companies using Azithromycin ingredient
Treatment:
Zmax is used for treating bacterial infections.
Dosage:
Zmax is available in for suspension, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 2GM BASE/BOT | FOR SUSPENSION, EXTENDED RELEASE | Discontinued | ORAL |